ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
Diagnostic Model Development for IC/BPS and Its Subtypes Using Clinical Indicators, Urinary Biomarkers, and Single-Cell Transcriptomic Analysis.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic, heterogeneous, and often debilitating condition. This condition is often misdiagnosed, as it overlaps significantly with other urinary infections, necessitating the development of new markers and targets to improve diagnosis and therapy. Tumor necrosis factor-α (TNF-α) participates in IC/BPS inflammation, but its role remains understudied. This study aimed to develop a diagnostic model for IC/BPS and its subtypes to uncover underlying mechanisms, new biomarkers, and TNF-α-targeted treatments. Patients with non-Hunner IC (NHIC, n = 196), Hunner IC (HIC, n = 56), and healthy controls (HC, n = 230) were enrolled in the study. A diagnostic model was developed based on key features identified by SHapley Additive exPlanations (SHAP) analysis. Molecular analysis using Gene Expression Omnibus (GEO) data and single-cell RNA sequencing (scRNA-seq) showed cellular heterogeneity and inflammatory networks. In silico TNF-α knockout was performed using scTenifoldKnk to investigate the function of TNF-α. Both NHIC and HIC subtypes present with severe clinical symptoms and dysregulated urinary biomarker profiles, with the HIC subtype showing significantly more severe symptoms and markedly increased levels of specific inflammatory mediators. A total of 127 machine learning (ML) models were constructed, of which most reached an AUC of 1.000 in training and external validation cohorts. Lasso+plsRglm was identified as the optimal diagnostic model. Core diagnostic features included nocturia frequency (NUF), visual analogue scale (VAS), functional bladder wall thickness (BWT), and TNF-α. Transcriptomics identified inflammation-related patterns and pathways between IC/BPS subtypes. scRNA-seq identified 12 cell types and an elevated inflammatory state. We discovered a TNF-α-driven inflammatory network influencing intergroup heterogeneity of IC/BPS, identified candidate diagnostic biomarkers to differentiate IC/BPS from HC, and highlighted possible therapeutic targets, thereby laying the groundwork for future clinical translation research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.